Paper Details

  1. Home
  2. Paper Details

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Author: ArnanMontserrat, BaerMaria R, BrevardJulie, CortesJorge E, De BottonStephane, DinnerShira N, DonnellanWill, FerrellP Brent, ForsythSanjeev, GuichardSylvie M, HenrickPatrick, JonasBrian A, KellyPatrick, LeeSangmin, MarzacChristophe, MohamedHesham, MontesinosPau, PigneuxArnaud, PrebetThomas, RécherChristian, SchillerGary J, SchwarerAnthony P, SeiterKaren P, SweeneyJennifer, WangEunice S, WattsJustin M, WeiAndrew H, YangJay

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.

Overview

This phase 1/2 study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), in patients with acute myeloid leukaemia or myelodysplastic syndrome harboring mutant IDH1.
Paper Details　
Original Abstract of the Article :
Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, as monotherapy or in combinati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3026(22)00292-7

データ提供：米国国立医学図書館（NLM）

Olutasidenib: A New Hope for IDH1-Mutated Cancers

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are serious blood cancers. This study investigated the safety and efficacy of a new drug, olutasidenib, for treating IDH1-mutated AML and MDS.

A Promising Oasis: Olutasidenib's Potential for Treatment

The study showed that olutasidenib, a potent inhibitor of mutant IDH1, demonstrated a favorable safety profile and promising clinical activity in patients with IDH1-mutated AML and MDS. This finding offers a potential new treatment option for these difficult-to-treat cancers. It's like discovering a hidden oasis in the desert—a source of hope for patients seeking effective treatment options.

Navigating Cancer Treatment: Seeking Personalized Solutions

Cancer treatment is often a complex and personalized journey. This study highlights the importance of understanding the specific genetic mutations driving a patient's cancer and tailoring treatment accordingly. This personalized approach, combined with the use of targeted therapies like olutasidenib, can improve the chances of successful treatment and long-term survival.

Dr. Camel's Conclusion

This study offers a glimmer of hope for patients with IDH1-mutated AML and MDS. Olutasidenib's promising safety and efficacy profile highlight the power of targeted therapies in the fight against cancer. It's a reminder that even in the vast and unforgiving desert of cancer research, new discoveries can emerge, offering hope for patients and their families.
Date :
  1. Date Completed 2022-12-27
  2. Date Revised 2022-12-30
Further Info :

Pubmed ID

36370742

DOI: Digital Object Identifier

10.1016/S2352-3026(22)00292-7

Related Literature

Article Analysis
・Effects of olutasidenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.